COMPANY PROFILE

Moonwalk Biosciences

Explore full profile

Adipose-targeted RNAi medicines for obesity and cardiometabolic disease

South San Francisco, United StatesFounded 2022Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Moonwalk Biosciences

Moonwalk Biosciences is a South San Francisco and San Diego biotechnology company developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. Led by CEO and co-founder Alex Aravanis, M.D., Ph.D., Moonwalk combines human genetics, epigenomics and multi-omics discovery with proprietary adipose-selective siRNA chemistry licensed from Suzhou Siran Biotechnology to modulate non-incretin pathways in fat tissue while aiming to preserve lean mass and enable infrequent dosing. Lead candidate MW101 is advancing through IND-enabling studies toward first-in-human trials planned for late 2027, with additional tissue-targeted siRNA programs in the pipeline; Stephen Djedjos, M.D., joined as SVP Clinical Development. In September 2026 Moonwalk closed an oversubscribed $70 million Series B co-led by Alpha Wave and YK Bioventures, with Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures. Sources: Business Wire / Moonwalk 2026; BioSpace.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: South San Francisco, United States
Employees: 21
Open positions: None listed
Dealroom signal: 62.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Genetics and genomics, Core AI, Epigenetics, Spinout, Genome Engineering, Biotech and Pharma, AI Drug Discovery, AI Applications, DT and LS, science-based
Technology: Artificial Intelligence
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jan 2024	$46M	$182M	GV · Khosla Ventures · ARCH Venture Partners · Future Ventures	↗
SEEDOther financing	Jun 2023	$11M	$46M	GV · YK Bioventures · Khosla Ventures · Alpha Wave Global	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Moonwalk Biosciences website traffic

Latest recorded traffic for Moonwalk Biosciences is 2.8K monthly website visits, up 0% over the last three months. Moonwalk Biosciences's team declined 4.5% over the past year.

Latest monthly visits2.8K 3-month web change0% 1-year team growth-4.5%

Monthly website visitsJan 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Scientist | Engineer, Machine Learning | BioinformaticsSouth San Francisco, CA · Data Science & Engineering · Jul 6, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CHChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa	Glasgow, United Kingdom	Operational	196	$104M	$200M
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
BIbit.bioDeveloping a scalable technology platform capable of producing consistent batches of every human cell	Cambridge, United Kingdom	Operational
ELEpigene LabsHelping cancer researchers develop new treatments and drugs by providing them with data-driven insights	Paris, France	Operational
LTLodo TherapeuticsDrug discovery and development company	New York City, United States	Acquired
SBScenic BiotechGenetic modifier therapies for rare inherited diseases	Amsterdam, Netherlands	Operational
SBSequentia BiotechSequentia Biotech developed MICK, a digital decision support system helping healthcare professionals in integrating microbiome analysis into clinical practice	Barcelona, Spain	Operational
DGDeep GenomicsDeep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies	Toronto, Canada	Operational